Ruxolitinib for treating graft-versus-host disease

Published on 04 Jun 2024
Last Updated on 04 Jun 2024

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended:

• Ruxolitinib 5 mg, 15 mg and 20 mg tablets for treating grades II to IV acute graft-versus-host disease (GVHD) in patients who have an inadequate response to corticosteroids.

Funding status

Ruxolitinib 5 mg, 15 mg and 20 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 August 2024.

MAF assistance does not apply to ruxolitinib for treating moderate to severe chronic GVHD in patients who have an inadequate response to corticosteroids.

Ruxolitinib for treating graft-versus-host disease (Published 4 Jun 24) [PDF, 125 KB]

PES Ruxolitinib for treating graft-versus-host disease (Published 4 Jun 24) [PDF, 109 KB]